Lives unaffected by cystic fibrosis

DRUG DEVELOPMENT PIPELINE

Back to the Drug Development Pipeline

ACG-701 (ARV-1801)

Phase One

Phase One

Therapeutic Approach

Anti-Infective

ACG-701 (formerly ARV-1801) is a version of sodium fusidate. It is a compound that is used to treat methicillin-resistant Staphlococcus aureus, a cause of some CF lung infections, and may also decrease inflammation and mucus production. Socium fusidate has been used in Europe, but it has never been approved in the U.S. This potential comes in oral tablet form.

Status

A phase 2 study to test the safety and effectiveness of ACG-701 in people with CF is planned.

Sponsor

This program is sponsored by Aceragen.



Contact us about ACG-701 (ARV-1801) >